FDA Nixes Biosimilar Guidance Over Burden Concerns
The U.S. Food and Drug Administration on Thursday scrapped draft guidance that explained how biosimilar makers can show that their products have the same structure and function as innovator biologics, concluding...To view the full article, register now.
Already a subscriber? Click here to view full article